FDG PET imaging in hereditary thyroid cancer

European Journal of Surgical Oncology

Volumn 29, Issue 10, 2003, Pages 922-928

  Boer A ^a   Szakall Jr S ^b   Klein, I ^c   Kasler M ^a,d   Vincze, B ^a   Tron L ^b,e   Godeny M ^a   Herzog, H ^f   Peter I ^a   Ésik, Olga ^a,d  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c INSTITUTE OF ENZYMOLOGY   (Hungary)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^f FORSCHUNGSZENTRUM JÜLICH   (Germany)

Author keywords

Familial medullary thyroid carcinoma; Multiple endocrine neoplasia type 2; Positron emission tomography; RET proto oncogene; Thyroidectomy; Ultrasonography

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ECHOGRAPHY; FAMILIAL CANCER; FEMALE; GENE MUTATION; HETEROZYGOTE DETECTION; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE ENDOCRINE NEOPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCHOOL CHILD; SUBTOTAL THYROIDECTOMY; THYROID CANCER; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TUMOR LOCALIZATION; TUMOR VOLUME; WHOLE BODY SCINTISCANNING;

EID: 10744225118     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0748-7983(03)00137-9     Document Type: Article

References (26)

1. Marsh DJ, Learoyd DL, Robinson BG. Medullary thyroid carcinoma: recent advances and management update. Thyroid 1995; 5: 407-24.
2. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C et al. Consensus. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86: 5658-71.
3. Lips CJM. Clinical management of the multiple endocrine neoplasia syndromes: results of a computerized opinion poll at the Sixth International Workshop on Multiple Endocrine Neoplasia and von Hippel-Lindau disease. J Intern Med 1998; 243: 589-94.
4. Klein I, Ésik O, Homolya V, Szeri F, Váradi A. Molecular genetic diagnostic program of multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma syndromes in Hungary. J Endocrinol 2001; 170: 661-6.
5. Lipinski B, Herzog H, Rota Kops E, Oberschelp W, Müller-Gärtner HW. Expectation maximization reconstruction of positron emission tomography images using anatomical magnet resonance information. IEEE Trans Med Imaging 1997; 16: 129-36.
6. Brandt-Mainz K, Müller SP, Görges R, Sailer B, Bockisch A. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med 2000; 27: 490-6.
7. Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P et al. Flourine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 2001; 28: 1671-6.
8. Gasparoni P, Rubello D, Ferlin G. Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma. J Endocrinol Invest 1997; 20: 527-30.
9. Musholt TJ, Musholt PB, Dehdashti F, Moley JF. Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study. Surgery 1997; 122: 1049-60.
10. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 2002; 43: 66-71.
11. Alexander HR, Jensen RT. Pancreatic endocrine tumors. In: DeVita V jr, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology, 6th edn. Philadelphia: Lippincott-Williams and Wilkins, 2001: 1788-813.
12. Jensen RT, Doherty GM. Carcinoid tumors and the carcinoid syndrome. In: DeVita V Jr, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology, 6th edn. Philadelphia: Lippincott-Williams and Wilkins, 2001: 1813-33.
13. Ésik O, Szavcsur P, Szakáll S Jr, Bajzik G, Repa I, Dabasi G et al. Angiography effectively supports the diagnosis of hepatic metastases in medullary thyroid cancer. Cancer 2001; 91: 2084-95.
14. Feldman GL, Edmonds MW, Ainsworth PJ, Schuffenecker I, Lenoir GM, Saxe AW et al. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG → ATG) mutation. Surgery 2000; 128: 93-8.
15. Wells SA Jr, Chi DD, Toshima K, Dehner LP, Coffin CM, Dowton B et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994; 220: 237-50.
16. Dralle H, Scheumann GFW, Proye C, Bacourt F, Frilling A, Limbert F et al. The value of lymph node dissection in hereditary medullary thyroid carcinoma: a retrospective, European, multicentre study. J Intern Med 1995; 238: 357-61.
17. Skinner MA, Wells SA Jr. Medullary carcinoma of the thyroid gland and the MEN2 syndromes. Semin Pediatr Surg 1997; 6: 134-40.
18. Learoyd DL, Marsh DJ, Richardson A-L, Twigg SM, Delbridge L, Robinson BG. Genetic testing for familial cancer. Consequences of RET proto-oncogene mutation analysis in multiple endocrine neoplasia, type 2. Arch Surg 1997; 132: 1022-5.
19. Frank-Raue K, Höppner W, Buhr H, Herfarth C, Raue F. Results and follow-up in eleven MEN2A gene carriers after prophylactic thyroidectomy. Exp Clin Endocrinol Diabetes 1997; 103 (Suppl. 4): 76-8.
20. Wells SA Jr, Skinner MA. Prophylactic thyreoidectomy, based on direct genetic testing, in patients at risk for the multiple endocrine neoplasia type 2 syndromes. Exp Clin Endocrinol Diabetes 1998; 106: 29-34.
21. Dralle H, Gimm O, Simon D, Frank-Raue K, Görtz G, Niederle B et al. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian Experience. World J Surg 1998; 22: 744- 51.
22. Hotz HG, Runkel NSF, Frank-Raue K, Raue F, Buhr HJ. Prophylactic thyreoidectomy in MENIIA: does the calcitonin level correlate with tumor spread? Langenbeck's Arch Surg 1998; 383: 170-3.
23. Lallier M, St-Vil D, Giroux M, Huot C, Gaboury L, Oligny L et al. Prophylactic thyroidectomy for medullary thyroid carcinoma in gene carriers of MEN2 syndrome. J Pediatr Surg 1998; 33: 846-8.
24. Niccoli-Sire P, Murat A, Baudin E, Henry J-F, Proye C, Bigorgne J-C et al. Early or prophylactic thyroidectomy in MEN2/FMTC gene carriers: results in 71 thyroidectomized patients. Eur J Endocrinol 1999; 141: 468-74.
25. Frohnauer MK, Decker RA. Update on the MEN2A c804 RET mutation: is prophylactic thyroidectomy indicated? Surgery 2000; 128: 1052-7. Discussion. 1057-8.
26. Sanso GE, Domene HM, Garcia Rudaz MC, Pusiol E, de Mondino AK, Roque M et al. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children. Presence of C-cell malignant disease in asymptomatic carriers. Cancer 2002; 94: 323-30.